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Abstract
The mobilization of myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) to the cervix during chlamydial infection is
not fully understood, and the role of these cells in immunopathogenesis is largely unknown. As an effective vaccine to control chlamy-
dial infection is currently unavailable, understanding the regulation of the local immune response becomes a necessity. Therefore, mDC
and pDC populations were analysed in peripheral blood and cervical samples of controls and Chlamydia-positive women, with or with-
out mucopurulent cervicitis (MPC). Cervical cytokines and C-reactive protein levels in serum were quantiﬁed by ELISA and the chlamy-
dial infectious load by culture. Chlamydia trachomatis infection mobilized both mDCs and pDCs to the cervical mucosa. pDCs were
recruited more often in women with MPC (p <0.05) and they correlated signiﬁcantly with the chlamydial load, C-reactive protein levels
and cervical interleukin-8 (IL-8) levels. Upregulation of surface expression of co-stimulatory molecules (CD80, CD83 and CD86) on cer-
vical mDCs and pDCs was observed during chlamydial infection but was signiﬁcant only for mDCs. Signiﬁcantly higher levels of IL-1b,
IL-6 and IL-8 were observed in Chlamydia-positive women with MPC; however, after therapy, IL-8 levels decreased signiﬁcantly. Median
numbers of mDCs after therapy were signiﬁcantly higher in the cervix and blood of infected women as compared to the numbers of
pDCs, which were found to be lower in the cervix after therapy. These results thus suggest that during chlamydial infection, both
mDCs and pDCs are recruited to the cervix, but their number and possible immunological functions may differ with the pathological
condition. pDCs were associated more often with MPC and inﬂammatory factors, suggesting that they may possibly be involved in the
immunopathogenesis of infections due to Chlamydia.
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Introduction
As an obligate intracellular bacterial pathogen, Chlamydia tra-
chomatis causes many important human diseases worldwide
[1,2]. In India, a high prevalence rate of genital chlamydial
infection, up to 40%, has been reported among symptomatic
women [3–5]. As the most prevalent sexually transmitted
bacterium, C. trachomatis causes urethritis, cervicitis, salpingi-
tis and reproductive disorders, with sequelae often resulting
from scarring of the affected genital tissues [6]. The exact
pathological mechanism by which C. trachomatis induces scar-
ring is still not well understood.
The mucosal surface of the urogenital tract provides a
large site of entry for various pathogens, the immune
response to which strongly depends on the presence of dif-
ferent inﬁltrating immune cells. During chlamydial infection
[7], T-cell-mediated adaptive immune responses play a major
role in the clearance and resolution of infection.
Dendritic cells (DCs) are potent antigen-presenting cells,
playing a crucial role in the initiation and maintenance of T-
cell immunity [8]. Besides contributing to adaptive resistance
against microbial pathogens [9], DCs have also been
reported to be involved in chronic inﬂammation [10]. In per-
ipheral blood, two major subsets of DCs are present, the
CD123+ plasmacytoid DCs (pDCs) and the CD11c+ myeloid
DCs (mDCs). Both of these subsets express high levels of
HLA-DR and lack the lineage markers CD3 [11], CD14,
CD19, CD20, CD16 and CD56 [12]. In humans, pDCs and
mDCs have been shown to be associated with various
pathological and disease conditions, e.g. viral infections
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[13–16], bacterial infections [17], parasitic infections [18],
fungal infections [19], cancerous conditions [20–23], systemic
lupus erythematosus [24], rheumatoid arthritis [25], coron-
ary artery disease [26] and inﬂammatory skin disease [27].
The cervical mucosa is also reported to contain numerous
DCs, interdigitating with the epithelial cells [28] and these
DCs are often CD1a-positive [29]. A previous study by
Bontkes et al. [30] found both pDCs and mDCs in the
female cervix during cervical carcinoma, but no information
is available concerning the mobilization of these two subsets
to the cervix during bacterial infections. We have previously
shown the enhancement in CD4+ T-cells, CD8+ T-cells and
dendritic cellular phenotypes in cervical samples from Chla-
mydia-positive women [31], but the recruitment of these two
DC subsets to the cervical mucosa during C. trachomatis
infection was not studied.
Therefore, in the present study, the mDC and pDC
populations in peripheral blood and cervical mucosa of
healthy controls and Chlamydia-positive women, with or
without mucopurulent cervicitis (MPC), were analysed to
determine their role in inﬂammation. The populations of
these subsets were correlated with the chlamydial load, C-
reactive protein (CRP) levels and cytokine levels. The
populations of these subsets were further studied in Chla-
mydia-positive women after full antibiotic therapy, in order
to determine their role in the pathogenesis of chlamydial
infection.
Materials and Methods
Study population
Between December 2005 and February 2007, 128 asymp-
tomatic women attending the family planning clinic and 69
women with signs and symptoms of cervicitis (mucopuru-
lent discharge) attending the Gynecology Outpatient
Department of Safdarjung Hospital, New Delhi, India were
enrolled for the study. Informed written consent was
obtained from all the participants. Women with a positive
urine pregnancy test result and those with a recent history
of antibiotic therapy or any history of previously treated
sexually transmitted infection were excluded from the
study. All women underwent general physical and speculum
examination. As variations in sex hormones are known to
inﬂuence cytokine concentrations and immune cell popula-
tions, including the mDCs and pDCs [32], cervical samples
were collected during the mid-menstrual cycle (median
13 days, range 9th to 15th day of the cycle). The study
received approval from the hospital’s ethics review com-
mittee.
Collection of samples
The vulva was examined for lesions, and the cervix for
warts, ulcers, ectopy, erythema or discharge, to determine
whether confounding venereal infections were present. After
cleaning of the cervix, cervical swabs and vaginal swabs
(HiMedia, Mumbai, India) were collected for diagnosis of
C. trachomatis and other sexually transmitted pathogens. For
collection of cervical cells, a cytobrush was rotated within
the cervical canal and then transferred to a sterile centrifuge
tube with phosphate-buffered saline (PBS) (pH 7.2), supple-
mented with 100 U penicillin/mL, 100 lg streptomycin/mL
and 100 lg glutamine/mL. All cytobrush samples yielded
negative results for blood contamination. Cervical washes in
5 mL of sterile saline and heparinized peripheral venous
blood (5 mL) were also collected.
Microbiology
The presence of chlamydiae in samples was conﬁrmed using
direct ﬂuorescenceanalysis with ﬂuorescein isothiocyanate
(FITC)-conjugated monoclonal antibodies (mAbs) against the
C. trachomatis major outer membrane protein (Microtrak,
Palo Alto, USA). A sample was considered to be positive
when ﬁve to ten elementary bodies were detected. Negative
samples were further conﬁrmed by PCR analysis using a pri-
mer speciﬁc for the 517-bp plasmid of C. trachomatis [33].
Gram-stained cervical smears were examined for the pre-
sence of yeast cells (candidiasis), and quantiﬁcation of poly-
morphonuclear leukocytes (PMNLs) per high-power ﬁeld
was performed using smears to ensure the presence of cer-
vicitis. Vaginal smears were analysed for clue cells for diagno-
sis of bacterial vaginosis. Wet mount microscopy was
performed for the diagnosis of Trichomonas vaginalis. Neisseria
gonorrhoeae, Mycobacterium hominis and Ureaplasma urealyti-
cum were detected by culture.
Isolation of cells from cervical samples
Cervical cells were isolated from the cytobrush by vigorously
rotating it against the sides of the transport tube after incu-
bating the sample with 5 mM DL-dithiothreitol (Sigma,
St Louis, MO, USA) at 37C for 15 min (to reduce the
mucus component of the sample). The cell suspension
obtained was then ﬁltered through a sterile 70=lm nylon
cell strainer (BD Biosciences, San Diego, CA, USA) and cen-
trifuged at 300 g for 10 min; the resultant pellet yielded
endocervical cells. The viability of cells was determined using
a Trypan blue exclusion assay.
Antibodies
DCs were identiﬁed by multi-parametric ﬂow cytometry
with the following mAbs: FITC-conjugated lineage cocktail
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LIN-1 (containing anti-CD3, anti-CD14, anti-CD16, anti-
CD19, anti-CD20 and anti-CD56), CD14–FITC, CD4–FITC,
CD8–FITC, CD123–phycoerythrin (PE) and HLA-DR–peridin
chlorophyll protein (BD Biosciences). In addition, allophyco-
cyanin-labelled anti-CD11c was purchased from eBiosciences
(San Diego, CA, USA). PE-labelled anti-CD80, CD83 and
CD86 were obtained from BD Biosciences. To measure
expression of CD80, CD83 and CD86 on CD123+ cells,
anti-CD123–PE–Cy5 and HLA-DR–allophycocyanin were
purchased from BD Biosciences.
For blood DCs, 100 lL of whole blood was incubated
with an antibody cocktail for 20 min at room temperature.
Erythrocytes were lysed with FACS Lysing Buffer (BD Bios-
ciences), and cells were washed with PBS containing 0.1%
(w/v) bovine serum albumin and 0.1% NaN3 to remove
unbound mAb and resuspended in 1% (w/v) paraformalde-
hyde in PBS. In total, 100 000 cervical cells/tube were incu-
bated with antibody cocktail for 25 min on ice and were
washed and ﬁxed following the protocol above. Cell pre-
parations were labelled in parallel, and included all isotype
control antibodies (BD Biosciences) appropriate for estab-
lishing the demarcation between negative and positive popu-
lations.
As previously described [29], cervical specimens exhibit a
high level of granularity and autoﬂuorescence, which could
be attributed to many factors. Background ﬂuorescence and
the presence of lymphocytes was minimized by introduction
of an acquisition gate on the forward-scatter vs. side-scatter
proﬁle, which included most of the mononuclear cell fraction
and provided reliable differentiation of these cells from
epithelial cells, lymphocytes and cell debris. Samples were
acquired using a FACS Calibur Cytometer and analysed with
Cell Quest software (Becton Dickinson, San Jose, CA, USA).
The gating strategy used to identify and quantify LIN)/DR+
cells is illustrated in Fig. 1.
mDCs and pDCs in cervical secretions were measured as
the number of events present per 100 000 cells taken for
the experiment. This number was then adjusted according to
the total number of cells obtained in that cervical sample.
These were ﬁnally presented as the number of events per
cervical sample. In the case of blood, the DC subsets
were counted as events per 100 lL of blood taken, and
were then calculated and represented as events per millilitre
of blood.
Quantiﬁcation of cytokines in cervical washes
Quantiﬁcation of interleukin (IL)-1b, IL-2, IL-4, IL-6, IL-8, IL-
10, IL-12, tumour necrosis factor (TNF)-a, interferon (IFN)-a
and IFN-c in cervical washes was performed with commer-
cially available ELISA kits (eBiosciences, San Diego, USA and
Diaclone, Cedex, France), in accordance with the manufac-
turer’s instructions.
Quantiﬁcation of chlamydial infectious load in cervical sam-
ples
Chlamydial infectious load in cervical samples was deter-
mined as infection-forming units (IFUs)/mL, as described else-
where [34].
Determination of CRP levels
CRP was determined using high-sensitivity hs-CRP ELISA
(Calbiotech, Spring Valley, CA, USA), according to the manu-
facturer’s instructions, and CRP levels above 2 mg/L were
considered to reveal a higher risk of chronic inﬂammation,
according to the manufacturer’s instructions.
Statistical analysis
The Kruskal–Wallis non-parametric test was used to com-
pare continuous variables among multiple groups. The non-
parametric Mann–Whitney U-test was used to compare DC
populations and cytokine concentrations. The Wilcoxon
signed rank test was used to compare DC numbers before
and after therapy. Correlation was determined with Spear-
man’s correlation coefﬁcient.
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FIG. 1. Quantiﬁcation of dendritic cell (DC) subsets in cervical
mucosa by ﬂow cytometric analysis. (a) Introduction of an acquisition
gate (R1) on the forward-scatter (FSC) vs. side-scatter (SSC) proﬁle
to select the mononuclear cell population. (b) Cervical DCs were
identiﬁed within gate R2 as ﬂuorescein isothiocyanate (FITC) cocktail
(contains anti-CD3, CD14, CD16, CD19, CD20, and CD56)-negative
and HLA-DR-positive. (c, d) Detection of HLA-DR+ CD11c+ myeloid
DCs and HLA-DR+ CD123+ plasmacytoid DCs, respectively. PerCP,
peridin chlorophyll protein; PE, phycoerythrin; APC, allophycocyanin.
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Results
Study population
Cervical C. trachomatis infection was diagnosed using direct
ﬂuorescence analysis in conjunction with PCR in 35 women
attending the family planning clinic (asymptomatic) and in 31
women attending the Gynecology Outpatient Department
(symptomatic). Fifteen Chlamydia-positive women, co-infected
with Candida spp., T. vaginalis, M. hominis, U. urealyticum or
N. gonorrhoeae, or having bacterial vaginosis, were excluded
from the study. Three Chlamydia-positive patients were
excluded, as the mononuclear cell count in the cervical cells
was less than 106 cells/mL. On the basis of diagnosis, the
women were divided into three groups. Group I (n = 28)
comprised uninfected healthy controls selected from among
women attending the family planning clinic; group II (n = 23)
comprised asymptomatic Chlamydia-positive women without
MPC (number of PMNLs <5); and group III (n = 25) com-
prised Chlamydia-positive women with MPC (number of
PMNLs >30) [35]. All women were age-matched, with no
signiﬁcant difference in their median ages.
Immune cell population in cervical mucosa
Flow cytometric analysis demonstrated the presence of
mDCs, pDCs, CD14+ monocytes, CD3+CD4+ T-cells and
CD3+CD8+ T-cells in both the Chlamydia-positive groups.
There was a signiﬁcant increase in the mean number of
CD4+ T-lymphocytes per 10 000 events in the cervical
mucosa of women with MPC, as compared to women with-
out MPC and to controls (573 vs. 375 and 234 respectively;
p <0.05). In contrast, in the cervical mucosa, the CD8+ T-cell
population was found to be higher during chlamydial infec-
tion, but not signiﬁcantly. The number of CD14+ monocytes
per 10 000 events was signiﬁcantly increased in women with
MPC, as compared to women without MPC and to controls
(474 vs. 259 and 138; p <0.05). These results are summar-
ized in Fig. 2.
mDC population in cervical mucosa and peripheral blood
Three of 28 healthy controls, one of the 23 Chlamydia-posi-
tive women without MPC and two of the 25 Chlamydia-posi-
tive women with MPC did not have mDCs in their cervical
samples. The median and range of absolute numbers of
mDCs/cervical sample are given in Table 1. Healthy controls
had a signiﬁcantly lower number of mDCs/cervical sample
than patients in the Chlamydia-positive groups (p <0.01). The
frequency (%) of mDCs in cervical samples of patients
(without MPC, median 0.074%, range 0–0.95%; with MPC,
median 0.068%, range 0–0.91%) was comparable to that in
blood samples of the same patients (without MPC, median
0.068%, range 0.02–0.32%; with MPC, median 0.064%, range
0.01–0.28%), although there was a signiﬁcant (p <0.05)
decrease in the absolute median numbers of mDCs/mL of
blood in Chlamydia-infected women without MPC, as com-
pared to controls. In cervical mDCs, signiﬁcantly higher
expression of CD83 and CD80 was observed in both
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FIG. 2. Lymphocyte subsets (CD4+ and CD8+ T-cells) and monocy-
tic cells in cervical mucosa of contols, Chlamydia trachomatis-positive
women with mucopurulent cervicitis (MPC) and without MPC
detected by ﬂow cytometry and expressed as mean number of cells
per 10 000 events on the y-axis.
TABLE 1. Absolute number of myeloid and plasmacytoid dendritic cells in cervical mucosa and blood samples
Myeloid dendritic cells Plasmacytoid dendritic cells
Control
CT-positive
Control
CT-positive
Without MPC With MPC Without MPC With MPC
Cervix 36 (0–1256) 1788 (0–40 170)a 720 (0–10 444)a,b 13 (0–1200) 1750 (0–33 840)a 3890 (1162–80 752)a
Blood 17 572 (3254–55 718) 1800 (458–13 786)a 10 800 (1326–27 556) 16 480 (3292–48 148) 7216 (4637–15 430)a 6240 (3341–22 382)a
CT, Chlamydia trachomatis; MPC, mucopurulent cervicitis.
The data represent median values for absolute numbers of myeloid and plasmacytoid dendritic cells (DCs) in cervical mucosa (DCs/cervical sample) and blood (DCs/mL
blood). Ranges are given in parentheses..
ap <0.05 of individual patient groups as compared to controls (Mann–Whitney U-test).
bp <0.05 of the CT-positive group with MPC as compared to that without MCP (Mann–Whitney U-test).
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Chlamydia-positive groups than in controls (p <0.05). Expres-
sion of CD86 was higher in both Chlamydia-positive groups,
but the difference was signiﬁcant (p <0.05) only in women
with MPC (Table 2).
pDC population in cervical mucosa and peripheral blood
Five of the 28 healthy controls and three of the 23 Chla-
mydia-positive women without MPC did not have pDCs in
their cervical samples. All the women with MPC had pDC
in their cervical samples. The median and range of abso-
lute numbers of pDCs/cervical sample are given in Table 1.
Healthy controls had a signiﬁcantly (p <0.001) lower num-
ber of pDCs in their cervical samples than Chlamydia-
infected women. In comparison to cervical samples, there
was a signiﬁcant decrease in absolute numbers of pDCs/
mL of blood in women infected with Chlamydia, as com-
pared to controls. The decrease was more pronounced in
women with MPC. Expression of all co-stimulatory mole-
cules was higher in pDCs in Chlamydia-positive women
than in controls, but was signiﬁcant (p <0.05) only for
CD80 (Table 2).
Concentration of cytokines in cervical washes and their cor-
relation with DC populations
The median levels of IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12, TNF-a, IFN-a and IFN-c in cervical washes of controls
and Chlamydia-positive women, before and after therapy are
shown in Table 3. The detection limit for all the cytokines
was 2 pg/mL, as described by the manufacturers. Before
therapy, signiﬁcantly higher levels of IL-1b and IL-6
(p <0.05) were observed in Chlamydia-positive women with
MPC than in those without MPC. IL-8 levels were signiﬁ-
cantly higher (p <0.05) in Chlamydia-positive women with
MPC than in those without MPC and controls. IL-4 levels
were below detection limits in all the samples. After ther-
apy, IL-8 levels in women with MPC showed signiﬁcant
downregulation (p <0.01) (Table 3). No other cytokine
showed any signiﬁcant change in levels after therapy.
Before therapy, a signiﬁcant correlation (r = 0.65; p <0.05)
was observed between the number of mDCs/cervical sam-
ples and levels of IL-12 in Chlamydia-positive women with-
out MPC. The number of pDCs in Chlamydia-positive
women with MPC showed a signiﬁcant correlation with
TABLE 2. Phenotypic characterization of dendritic cell subsets in cervical mucosa
Co-stimulatory
molecules
Percentage expression on mDCs Percentage expression on pDCs
CT-positive
Controls
CT-positive
ControlsWithout MPC With MPC Without MPC With MPC
CD80 16.0 ± 2.8a 26.0 ± 3.4a 02.0 ± 0.7 03.9 ± 2.4 06.3 ± 3.0b 02.5 ± 1.3
CD83 24.0 ± 3.6a 30.0 ± 4.2a 11.0 ± 0.6 04.7 ± 0.9 07.1 ± 2.6 03.3 ± 1.2
CD86 53.0 ± 4.2 65.0 ± 7.2b 32.0 ± 5.1 02.2 ± 0.4 04.2 ± 2.1 01.7 ± 0.7
CT, Chlamydia trachomatis; MPC, mucopurulent cervicitis; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell.
The data represent co-stimulatory molecules on mDCs and pDCs in cervical mucosa.
ap <0.05 of individual patient groups as compared to controls (Mann–Whitney U-test).
bp <0.05 of the CT-positive group with MPC as compared to controls (Mann Whitney U-test).
TABLE 3. Cytokine concentrations in cervical washes before and after therapy
Control
CT-positive CT-positive
With MPC
(before therapy)
Without MPC
(before therapy)
With MPC
(after therapy)
With MPC
(after therapy)
IL-1b 79.24 (UDL–350.14) 37.62 (UDL–99.86) 96.90 (8.70–298.0)a 54.37 (UDL–296.45) 90.25 (UDL–304.21)
IL-2 4.59 (UDL–30.35) 3.37 (UDL–13.57) 2.98 (UDL–16.42) 3.47 (UDL–28.34) 2.85 (UDL–15.93)
IL-6 29.46 (UDL–188.70) 9.36 (UDL–39.63) 70.96 (UDL–190.60)a 15.41 (UDL–173.93) 43.46 (UDL–201.48)a
IL-8 89.9 (UDL–247.57) 137.4 (13.74–375.9) 551.58 (32–1074.0)b 112.31 (4.52–295.93) 93.17 (13.69–231.94)
IL-10 7.10 (UDL–22.86) 6.64 (UDL–22.96) 11.68 (UDL–30.91) 8.31 (UDL–24.61) 9.28 (UDL–27.83)
IL-12p40 157.35 (UDL–542.89) 267.5 (24.85–727.56) 166.25 (UDL–532.87) 183.82 (19.27–562.37) 159.74 (2.48–527.17)
IFN-c 145.78 (19.65–589.73) 173.24 (7.33–566.6) 136.96 (UDL–330.6) 152.75 (5.38–478.59) 141.72 (5.48–394.26)
TNF-a 1.47 (UDL–6.61) 1.45 (UDL–13.73) 1.58 (UDL–6.87) 1.48 (UDL–10.67) 1.51 (UDL–5.85)
IFN-a 20.42 (UDL–74.95) 29.69 (UDL–92.57) 38.57 (UDL–95.31) 23.60 (UDL–77.39) 26.86 (UDL–85.45)
CT, Chlamydia trachomatis; MPC, mucopurulent cervicitis; UDL, under detection limit; IL, interleukin; IFN, interferon; TNF, tumour necrosis factor.
The data represent median values. Ranges are given in parentheses.
ap <0.05 of the CT-positive women with MCP as compared to CT-positive women without MCP (Mann–Whitney U-test).
bp <0.01 of the CT-positive group with MPC as compared to both of the other groups (Mann–Whitney U-test).
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IL-8 levels (r = 0.58; p <0.05) and a less apparent correla-
tion with IL-6 (r = 0.37).
After therapy, no correlation among mDC and pDC
populations and cytokine levels was observed.
Correlation of mDC and pDC with chlamydial infectious
load and CRP
The chlamydial infectious load was determined by inoculating
cervical samples into HeLa 229 cells as described elsewhere
[34], and IFUs/mL were quantiﬁed. In cervical mucosa, the
number of mDCs/cervical sample showed a signiﬁcant corre-
lation with chlamydial IFUs/mL (r = 0.524; p <0.05) in Chla-
mydia-positive women without MPC. A positive, non-
signiﬁcant correlation was found between chlamydial IFUs/
mL and mDCs/cervical sample in women with MPC
(r = 0.312). In comparison, the number of pDCs/cervical
sample showed a signiﬁcant correlation with chlamydial IFUs/
mL in women both with and without MPC (r = 0.853,
p <0.001, and r = 0.724, p <0.01, respectively). The median
CRP levels were found to be signiﬁcantly higher in women
with MPC than in women without MPC (data not shown),
and showed a signiﬁcant correlation with pDCs/cervical sam-
ple (r = 0.675, p <0.05). No correlation was found between
the number of mDCs/cervical sample and CRP levels.
mDCs and pDCs in cervix and blood after resolution of
chlamydial infection
All Chlamydia-positive women were advised to undergo full
antibiotic therapy, and after 4–6 weeks, eight women from
each Chlamydia-positive group who returned for follow-up
were again enrolled. After treatment, none of the women in
group II was Chlamydia-positive, as revealed by PCR and cul-
ture. One patient with MPC (CT18M) was found to be Chla-
mydia-positive even after therapy, although the number of
PMNLs was less than ten, with no mucopurulent discharge.
Comparison of paired measurements of mDCs and pDCs in
cervical samples in only the patients with chlamydial infection
who returned for follow-up evaluation revealed a signiﬁcant
increase in the number of mDCs after therapy, in both Chla-
mydia-infected groups (Fig. 3a,b). The median number of
pDCs was lower in both the Chlamydia-infected groups after
therapy. The pDC number was signiﬁcantly lower in women
with MPC after therapy (Fig. 3c,d). The median numbers of
mDCs and pDCs in peripheral blood and cervical samples
before and after therapy are given in Table 4. The relative
frequency of mDCs in cervical samples signiﬁcantly increased,
from 0.074% before therapy to 0.19% after therapy in
group II (p <0.05) and from 0.068% before therapy to 0.11%
after therapy in group III (non signiﬁcant). The relative fre-
quency of pDCs in cervical samples of women with MPC sig-
niﬁcantly decreased from 0.18% before therapy to 0.04%
after therapy (p <0.05).
Discussion
In women, chlamydial infections are often asymptomatic, and
subsequent re-infection leads to inﬂammatory responses with
pathological sequelae [36]. In the peripheral circulation, the
LIN)/DR+ DCs comprise 0.1–2% of the total peripheral
blood mononuclear cells in healthy individuals, and the
majority of these cells express either CD11c or CD123 mar-
kers [37]. The initiative to study the DC subsets during
C. trachomatis infection was prompted by the currently
incomplete knowledge concerning these subsets.
Women with and without MPC were enrolled for the
study of differential recruitment of DC subsets during non-
inﬂammatory and inﬂammatory conditions. The resulting data
showed that, during C. trachomatis infection, both mDCs and
pDCs are recruited to the site of infection. The mDC popu-
lation in the cervix was more abundant during non-inﬂamma-
tory conditions, whereas the pDC population was more
abundant during inﬂammatory conditions.
This was supported by the fact that, in blood, the num-
bers of mDCs were signiﬁcantly reduced, as compared to
controls, in women without MPC but not in women with
MPC, suggesting greater mobilization of mDCs to an infected
but non-inﬂamed cervix. As compared to controls, in both
of the Chlamydia-positive groups, signiﬁcant upregulation of
the CD83 and CD80 markers on mDCs was observed, with
stronger upregulation in women with MPC, suggesting the
presence of a larger number of matured mDCs with
increased co-stimulatory molecule expression during inﬂam-
mation of the cervix. The lower numbers of mDCs/cervical
sample in women with MPC may be a possible explanation
for the incomplete clearance of chlamydiae and, therefore,
the pathogenesis of chlamydial infection.
The median chlamydial infectious load in women without
MPC was found to be signiﬁcantly lower than that in women
with MPC (data not shown). pDCs, on the other hand, were
more prevalent in an inﬂamed cervix than in a non-inﬂamed
cervix, with signiﬁcantly lower numbers in the blood of Chla-
mydia-positive women than in controls. pDCs were also sig-
niﬁcantly correlated with chlamydial infectious loads in both
groups, with CRP levels in the serum of women with MPC,
and with the number of PMNLs in women with MPC (data
not shown).
No signiﬁcant upregulation of the expression of any co-sti-
mulatory molecule, except CD80, on pDCs of Chlamydia-
positive women was observed, which suggests that such
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molecules may not be actually involved in initiating immune
responses, but could have some role in the pathogenesis of
chlamydial infection. However, this is hypothetical, as the
expression of the reported maturation marker for pDCs
[38], the inducible co-stimulatory ligand (ICOS-L), was not
measured. No apparent correlation of mDCs was observed
with the chlamydial infectious load in women with MPC, thus
suggesting that C. trachomatis infection attracts more pDCs
than mDCs to the cervix.
An inverse correlation of CRP levels with mDC numbers
has been shown previously [25], but no correlation was
found in the current study (data not shown). pDCs were
also found to be more abundant in extensive coronary artery
disease, according to authors who suggested a role for them
in plaque progression [26]. A recent study by Brunham et al.
mDC in women without MPC
0
2500
5000
7500
10000
12500
15000
17500
20000
m
D
Cs
/c
er
vi
ca
l s
am
pl
e
CT02
CT04
CT07
CT11
CT15
CT18
CT19
CT22
Chlamydia infected Infection resolved
m
D
Cs
/c
er
vi
ca
l s
am
pl
e
mDC in women with MPC
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Infection resolvedChlamydia infected
CT01M
CT03M
CT08M
CT15M
CT17M
CT18M
CT24M
CT25M
pDC in women without MPC
0
2500
5000
7500
10000
12500
15000
17500
20000
pD
Cs
/c
er
vi
ca
l s
am
pl
e
CT02
CT04
CT07
CT11
CT15
CT18
CT19
CT22
Chlamydia infected Infection resolved
pD
Cs
/c
er
vi
ca
l s
am
pl
e
pDC in women with MPC
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Chlamydia infected Infection resolved
CT01M
CT03M
CT08M
CT15M
CT17M
CT18M
CT24M
CT25M
(a) (b)
(c) (d)
FIG. 3. Change in number of dendritic cells (DCs) in cervical samples of Chlamydia-positive women without or with mucopurulent cervicitis
(MCP) after resolution of chlamydial infection. (a, b) Myeloid DCs (mDCs) in cervical samples of eight women with or without MCP who
returned for follow-up after resolution. (c, d) Similar data for plasmacytoid DCs (pDCs) in cervical samples.
TABLE 4. Absolute number of myeloid and plasmacytoid
dendritic cells in cervical mucosa and blood samples before
and after resolution of infection
CT-positive without
MPC
CT-positive with MPC
Before
therapy
After
therapy
Before
therapy
After
therapy
Cervix
mDCs 1788 5384a 720 3917a
pDCs 1750 983a 3890 413a
Blood
mDCs 1800 5860a 10 800 18 560
pDCs 7216 13 277 6240 17 472a
CT, Chlamydia trachomatis; MPC, mucopurulent cervicitis; mDC, myeloid dendri-
tic cell; pDC, plasmacytoid dendritic cell.
The data represent median values for all cases before therapy and of the eight
follow-ups after therapy.
ap <0.05 as compared to paired measurements (Wilcoxon signed ranked test).
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[39] reported the persistence of Chlamydia inside DCs. This
study, when compared with the current results, suggests that
pDCs are not efﬁcient in presenting chlamydial antigens to
T-cells, and can be used by C. trachomatis for its survival and
persistence, leading to inﬂammation.However, further studies
are required to test this hypothesis.
The cervical cytokines in women were measured before
therapy, and signiﬁcantly higher levels of IL-1b, IL-6 and IL-8
were found in Chlamydia-positive women, with the levels of
IL-1b and IL-8 being considerably higher in women with
MPC. Following complete antibiotic therapy, the cytokine
levels in both of the Chlamydia-positive groups showed little
variation, as in the case of IL-1b, IL-2, IL-10, IL-12p40, IFN-c,
TNF-a and IFN-a. In contrast, IL-8 levels in women with
MPC decreased signiﬁcantly after therapy and tended to
become equivalent to the levels in controls. Before therapy,
the number of mDCs/cervical samples was signiﬁcantly cor-
related with cervical IL-12 levels in women without MPC,
and pDCs correlated with IL-8 levels in women with MPC.
No such correlation was observed after therapy, which sug-
gests that, during infection, recruitment of particular DC
subset decides the cytokine proﬁle in cervical mucosa.
As for cytokine production by these subsets, previous stu-
dies have shown production of IFN-a by pDCs upon viral
challenge [40–42], and production of IL-12 by mDCs and IL-
12, IL-10 and IFN-a by pDCs in response to fungal infections
[19]. pDCs have been reported to express TLR9 and, upon
stimulation with CpG motifs, they have been reported to
express IFN-a, IL-6 [43] and IL-12p70 [44] in a mouse
model, but the cytokine secretion pattern of pDCs upon
bacterial challenge in humans is yet to be ascertained fully.
Secretion of IL-12 by mDCs has been observed after incuba-
tion with mycobacteria [17], and secretion of IL-10 and IL-23
after incubation with Helicobacter pylori [45]. Few studies
have been performed where these DCs were stimulated
with lipopolysaccharide (LPS) in order to determine the
cytokine secretion patterns [46]. These studies revealed that,
upon LPS stimulation, mDCs produce large amounts of IL-8.
This is in contrast to the current results, where a signiﬁcant
correlation between IL-8 and the number of pDCs is estab-
lished. No signiﬁcant increase in levels of IFN-a during chla-
mydial infection was found in the current study, which is
somewhat in concordance with the results of Dai et al. [47],
who have also shown an absence of induction of IFN-a pro-
duction from pDCs when they are stimulated with LPS. The
current results may shed new light on chlamydial pathogen-
esis, but the conclusions are still hypothetical, due to two
limitations of the study: (i) the low cell numbers, making it
impossible to separate the subsets in order to determine the
expression of cytokines upon stimulation with C. trachomatis;
and (ii) the fact that cytokines such as IL-12 are secreted by
other cell populations, e.g. macrophages, which outnumber
DCs in the cervix.
After resolution of infection, surprisingly, increased levels
of mDCs were found in both the cervix and blood of Chla-
mydia-positive women. The levels of pDCs, on the other
hand, were lower in both of the groups after infection was
resolved, except for one patient (CT18M) in group III
(MCP), in whom the infection was not resolved, conﬁrming
the hypothesis that C. trachomatis mobilizes pDCs in the cer-
vix in accordance with its load. Many studies have been pre-
viously carried out concerning the population of DCs before
and after therapy in blood samples, but very few have been
undertaken to enumerate DCs at mucosal surfaces after
therapy [14]. The increase in the number of DCs in blood
can be explained by the fact that, because the infection is
resolved, the DCs are not migrating from the blood to the
cervix. We propose that lower numbers of mDCs in the
cervix before therapy could be due to migration of these
DCs to the lymph nodes for initiation of immune responses;
however, after resolution of infection, these mature DCs
return to the cervix, thereby increasing the numbers. A sig-
niﬁcant increase in the number of pDCs after therapy has
been shown by many authors [40,48], but these results were
obtained from analysis of blood. In the current study, the
number of pDCs after therapy was lower in women without
MPC, but the reduction was not signiﬁcant by comparison
with women with MPC, in whom the decrease in numbers
after therapy was highly signiﬁcant. This further conﬁrms the
hypothesis that pDCs are more involved in inﬂammation.
In conclusion, it has been shown here that both of the
DC subsets are attracted to the site of chlamydial infection,
with a greater prevalence of pDCs in inﬂammatory condi-
tions. pDC numbers correlated with chlamydial load and,
after resolution of infection, a sudden drop in these numbers
was observed. This suggests a possible role of pDCs in the
immunopathogenesis of chlamydial infection. A hypothesis
that emerges from these results is that pDCs are not able to
clear the infection, and somehow allow the persistence of
Chlamydia inside them. However, further studies are
required, as this study has the limitation that only a low
number of cells was obtained from the cervix, which hin-
dered the in vitro analysis of the two subsets. The uncertainty
about whether the mobilization is due to chlamydial infection
or other infections that also mobilize DCs to the cervix to
the same extent was also a limitation of this study. Regard-
less of its limitations, this study will contribute to our under-
standing of the interplay between Chlamydia and DCs, which
is of interest given the fact that a vaccine against
C. trachomatis is still unavailable. As DCs are being targeted
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as an efﬁcient adjuvant for delivery of chlamydial antigens,
this study could provide insights facilitating the production of
an efﬁcient vaccine for Chlamydia.
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